WO2012025553A1 - Système d'administration d'un médicament biologique particulaire à libération double contrôlée - Google Patents

Système d'administration d'un médicament biologique particulaire à libération double contrôlée Download PDF

Info

Publication number
WO2012025553A1
WO2012025553A1 PCT/EP2011/064511 EP2011064511W WO2012025553A1 WO 2012025553 A1 WO2012025553 A1 WO 2012025553A1 EP 2011064511 W EP2011064511 W EP 2011064511W WO 2012025553 A1 WO2012025553 A1 WO 2012025553A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
spray
polyelectrolyte
microspheres
composition
Prior art date
Application number
PCT/EP2011/064511
Other languages
English (en)
Inventor
Jean Paul Remon
Bruno De Geest
Stefaan De Koker
Johan Grooten
Chris Vervaet
Original Assignee
Universiteit Gent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Gent filed Critical Universiteit Gent
Publication of WO2012025553A1 publication Critical patent/WO2012025553A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin

Abstract

Cette invention concerne une composition comprenant une substance sacrificielle, un complexe de polyélectrolytes, et un ou plusieurs médicaments, chacun d'eux ayant un poids moléculaire d'au moins 1 000 daltons. Ladite composition est caractérisée en ce qu'elle peut être obtenue par séchage par atomisation. La composition selon l'invention peut être préparée sous forme de particules et sous forme de suspension de particules. L'invention concerne également des compositions pharmaceutiques utilisées pour une administration pharmacologique extracellulaire, ainsi que des compositions pharmaceutiques à libération pharmacologique double contrôlée.
PCT/EP2011/064511 2010-08-24 2011-08-24 Système d'administration d'un médicament biologique particulaire à libération double contrôlée WO2012025553A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1014122.4 2010-08-24
GBGB1014122.4A GB201014122D0 (en) 2010-08-24 2010-08-24 Particulate biologic drug delivery system

Publications (1)

Publication Number Publication Date
WO2012025553A1 true WO2012025553A1 (fr) 2012-03-01

Family

ID=42984553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/064511 WO2012025553A1 (fr) 2010-08-24 2011-08-24 Système d'administration d'un médicament biologique particulaire à libération double contrôlée

Country Status (2)

Country Link
GB (1) GB201014122D0 (fr)
WO (1) WO2012025553A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017257A1 (fr) * 1996-10-19 1998-04-30 Quadrant Healthcare (Uk) Limited Microcapsules poreuses et leur utilisation en tant que vehicules therapeutiques et diagnostiques
WO1998031346A1 (fr) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation de particules pour inhalation
WO2006064331A1 (fr) * 2004-12-17 2006-06-22 Medipol Sa Particules hydrophiles a base de derives de chitosanes cationiques
US20070172430A1 (en) * 2006-01-20 2007-07-26 Nastech Pharmaceutical Company Inc. Dry powder compositions for rna influenza therapeutics
EP2172193A1 (fr) * 2008-10-02 2010-04-07 Capsulution Nanoscience AG Compositions de nanoparticules améliorées de composés faiblement solubles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017257A1 (fr) * 1996-10-19 1998-04-30 Quadrant Healthcare (Uk) Limited Microcapsules poreuses et leur utilisation en tant que vehicules therapeutiques et diagnostiques
WO1998031346A1 (fr) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation de particules pour inhalation
WO2006064331A1 (fr) * 2004-12-17 2006-06-22 Medipol Sa Particules hydrophiles a base de derives de chitosanes cationiques
US20070172430A1 (en) * 2006-01-20 2007-07-26 Nastech Pharmaceutical Company Inc. Dry powder compositions for rna influenza therapeutics
EP2172193A1 (fr) * 2008-10-02 2010-04-07 Capsulution Nanoscience AG Compositions de nanoparticules améliorées de composés faiblement solubles

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
"Remington; The Science and Practice of Pharmacy", 2006, LIPPINCOTT WILLIAMS & WILKINS
B. G. DE GEEST, G. B. SUKHORUKOV, H. MOHWALD, EXPERT OPINION ON DRUG DELIVERY, vol. 6, 2009, pages 613
B. G. DE GEEST, N. N. SANDERS, G. B. SUKHORUKOV, J. DEMEESTER, S. C. DE SMEDT, CHEMICAL SOCIETY REVIEWS, vol. 36, 2007, pages 636
B. G. DE GEEST, S. DE KOKER, G. B. SUKHORUKOV, O. KREFT, W. J. PARAK, A. G. SKIRTACH, J. DEMEESTER, S. C. DE SMEDT, W. E. HENNINK, SOFT MATTER, vol. 5, 2009, pages 282
C. S. PEYRATOUT, L. DAHNE, ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, vol. 43, 2004, pages 3762
D. V. VOLODKIN, N. I. LARIONOVA, G. B. SUKHORUKOV, BIOMACROMOLECULES, vol. 5, 2004, pages 1962
E. DONATH, G. B. SUKHORUKOV, F. CARUSO, S. A. DAVIS, H. MOHWALD, ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, vol. 37, 1998, pages 2202
F. CARUSO, R. A. CARUSO, H. MOHWALD, SCIENCE, vol. 282, 1998, pages 1111
G. B. SUKHORUKOV, E. DONATH, S. DAVIS, H. LICHTENFELD, F. CARUSO, V. I. POPOV, H. MOHWALD, POLYMERS FOR ADVANCED TECHNOLOGIES, vol. 9, 1998, pages 759
G. B. SUKHORUKOV, H. MOHWALD, TRENDS IN BIOTECHNOLOGY, vol. 25, 2007, pages 93
G. DECHER, SCIENCE, vol. 277, 1997, pages 1232
G. SKIRTACH, A. M. JAVIER, O. KREFT, K. KOHLER, A. P. ALBEROLA, H. MOHWALD, W. J. PARAK, G. B. SUKHORUKOV, ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, vol. 45, 2006, pages 4612
GUERMONPREZ, P., SAVEANU, L., KLEIJMEER, M., DAVOUST, J., VAN ENDERT, P., AMIGORENA, S., NATURE, vol. 425, 2003, pages 397 - 402
J. F. QUINN, A. P. R. JOHNSTON, G. K. SUCH, A. N. ZELIKIN, F. CARUSO, CHEMICAL SOCIETY REVIEWS, vol. 36, 2007, pages 707
KOVACSOVICSBANKOWSKI, M., CLARK, K., BENACERRAF, B., ROCK, K. L., PROC. NATL. ACAD SCI. U.S.A., vol. 90, 1993, pages 4942 - 4946
O. E. SELINA, S. Y. BELOV, N. N. VLASOVA, V. I. BALYSHEVA, A. I. CHURIN, A. BARTKOVIAK, G. B. SUKHORUKOV, E. A. MARKVICHEVA, JOURNAL OF BIOORGANIC CHEMISTRY, vol. 35, 2009, pages 103
OUSA, C. R. E., GERMAIN, R. N., J EXP. MED, vol. 182, 1995, pages 841 - 851
R. DE ROSE, A. N. ZELIKIN, A. P. R. JOHNSTON, A. SEXTON, S. F. CHONG, C. CORTEZ, W. MULHOLLAND, F. CARUSO, S. J. KENT, ADVANCED MATERIALS, vol. 20, 2008, pages 4698
R. PALANKAR, A. G. SKIRTACH, O. KREFT, M. BEDARD, M. GARSTKA, K. GOULD, H. MOHWALD, G. B. SUKHORUKOV, M. WINTERHALTER, S. SPRINGER, SMALL, vol. 5, 2009, pages 2168
S. DE KOKER, B. G. DE GEEST, S. K. SINGH, R. DE RYCKE, T. NAESSENS, Y. VAN KOOYK, J. DEMEESTER, S. C. DE SMEDT, J. GROOTEN, ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, vol. 48, 2009, pages 8485
S. DE KOKER, T. NAESSENS, B. G. DE GEEST, P. BOGAERT, J. DEMEESTER, S. DE SMEDT, J. GROOTEN, JOURNAL OF IMMUNOLOGY, vol. 184, pages 203
S. F. CHONG, A. SEXTON, R. DE ROSE, S. J. KENT, A. N. ZELIKIN, F. CARUSO, BIOMATERIALS, vol. 30, 2009, pages 5178
SEXTON, P. G. WHITNEY, S. F. CHONG, A. N. ZELIKIN, A. P. R. JOHNSTON, R. DE ROSE, A. G. BROOKS, F. CARUSO, S. J. KENT, ACS NANO, vol. 3, 2009, pages 3391
SHEN, Z. H., REZNIKOFF, G., DRANOFF, G., ROCK, K. L., J IMMUNOL., vol. 158, 1997, pages 2723 - 2730
T. BOUDOU, Y. CROUZIER, K. REN, G. BLIN, C. PICART, ADVANCED MATERIALS, vol. 22, 2010, pages 441

Also Published As

Publication number Publication date
GB201014122D0 (en) 2010-10-06

Similar Documents

Publication Publication Date Title
Islam et al. Recent advances in chitosan-based nanoparticulate pulmonary drug delivery
Han et al. Biomaterial-assisted biotherapy: A brief review of biomaterials used in drug delivery, vaccine development, gene therapy, and stem cell therapy
Almeida et al. Solid lipid nanoparticles as a drug delivery system for peptides and proteins
Amidi et al. Chitosan-based delivery systems for protein therapeutics and antigens
Kunda et al. Nanocarriers targeting dendritic cells for pulmonary vaccine delivery
JP5841708B2 (ja) 表面被覆微粒子の医薬組成物
Cun et al. Particle engineering principles and technologies for pharmaceutical biologics
AU2002366267B2 (en) Pharmaceutical compositions in particulate form
WO2015192603A1 (fr) Émulsion huile dans eau ne contenant pas de tensioactif, et son utilisation
Yan et al. An overview of biodegradable nanomaterials and applications in vaccines
CN112245574A (zh) 一种负载全细胞组分的靶向输送系统及其应用
EP2898894A1 (fr) Particules nano-in-micro pour administration intradermique
KR20160112005A (ko) 친수성 활성 화합물의 나노캡슐화
Woo Park et al. Multifunctional delivery systems for advanced oral uptake of peptide/protein drugs
del Pozo-Rodríguez et al. Lipid nanoparticles as vehicles for macromolecules: nucleic acids and peptides
Kalam et al. Non-invasive administration of biodegradable nano-carrier vaccines
JP5491119B2 (ja) 薬物含有微粒子を含む医薬組成物およびその製造方法
EP3983003A1 (fr) Nanoparticules destinées à être utilisées dans la redirection contre la tumeur d'une réponse immunitaire non spécifique à une tumeur, sur la base d'une immunité préexistante
Hou et al. Up-to-date vaccine delivery systems: robust immunity elicited by multifarious nanomaterials upon administration through diverse routes
Chavda et al. Advanced particulate carrier-mediated technologies for nasal drug delivery
CN114288398B (zh) 基于全细胞组分的癌症疫苗系统在制备交叉预防或治疗异种癌症药物中的应用
EP2608774B1 (fr) Microsphères dégradables et poreuses à base de polyelectrolytes comme vecteurs de vaccins
Xiang et al. Nanoparticles, immunomodulation and vaccine delivery
JP2003514832A (ja) 微粒子製造に関する連続フロー法
Dobhal et al. Chitosan-Based nanoparticulate systems: Implication towards therapeutics application

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11755291

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11755291

Country of ref document: EP

Kind code of ref document: A1